论文部分内容阅读
目的探讨阿托伐他汀对脑梗死患者hs-CRP、MMP-9水平和血脂的影响。方法将74例脑梗死患者随机分为阿托伐他汀组及阿司匹林组各37例,分别给予阿托伐他汀及阿司匹林进行治疗,观察2组患者治疗前后hs-CRP、MMP-9和总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平变化。结果用药3个月后,阿托伐他汀组患者hs-CRP、MMP-9水平和TC、LDL-C水平与治疗前相比显著下降,且低于阿司匹林组,差异有统计学意义(P<0.05)。阿司匹林组患者治疗前后hs-CRP、MMP-9水平和TC、LDL-C水平变化差异无统计学意义(P>0.05)。结论阿托伐他汀可有效降低后脑梗死患者hs-CRP、MMP-9水平,降低患者炎性反应的发生,对患者血管进行保护,同时降低血脂水平,有利于疾病预后,值得临床推广应用。
Objective To investigate the effect of atorvastatin on hs-CRP, MMP-9 and blood lipid in patients with cerebral infarction. Methods A total of 74 patients with cerebral infarction were randomly divided into atorvastatin group and aspirin group, 37 patients were treated with atorvastatin and aspirin respectively. The changes of hs-CRP, MMP-9 and total cholesterol TC), low density lipoprotein cholesterol (LDL-C) levels. Results At 3 months after treatment, the levels of hs-CRP, MMP-9, TC and LDL-C in atorvastatin group were significantly lower than those before treatment and were lower than those in aspirin group (P < 0.05). The levels of hs-CRP, MMP-9, TC and LDL-C in aspirin group before and after treatment had no significant difference (P> 0.05). Conclusions Atorvastatin can effectively reduce the levels of hs-CRP and MMP-9 in patients with posterior cerebral infarction, reduce the occurrence of inflammatory reaction, protect the blood vessels of patients and decrease the blood lipid level, which is beneficial to the prognosis of the disease. It is worthy of clinical application.